

# ANNUAL REPORT 2019



## ABOUT THE REPORT

Clinical Research Malaysia (CRM) is proud to share our achievements and success stories in this 2019 Annual Report. We encourage our stakeholders, industry partners, investigators and members of the community to take a moment to read this 4th annual report, which contains information about the important work that our organization does to build a comprehensive research ecosystem in Malaysia.

For industry sponsors, the success of a sponsored research depends upon choosing the right country to conduct clinical trials. Speed, quality and reliability are essential criteria for a site to be awarded the study. Malaysia offers a compelling package to sponsors and contract research organizations (CROs) when it comes to conducting sponsored research.

Simply put, a very strong emphasis on patient safety and benefit is combined with a well-developed and equipped healthcare system that is manned by well-trained, highly qualified and English literate medical professionals. Moreover, Malaysia's multi-ethnic population provides sponsors and CROs with access to genetic diversity while the costs of conducting clinical trials are very competitive when compared to neighbouring countries in the region.

The long-term focus by the Malaysian Government is to make Malaysia a significant global player in clinical research and this is made possible through the establishment of CRM. CRM provides advance global health solutions for a brighter, more hopeful future for the people by providing speedy and reliable end-to-end clinical research support. CRM works together with its partners to create an impetus in delivering better services to its end clients and at the same time creating high-skilled job opportunities.

In this annual report, we will highlight CRM's milestones to showcase Malaysia's potential as the preferred hub for conducting clinical trials.

## INSIDE THIS REPORT

Foreword.....	4
Board of Directors.....	5
Organisation Chart.....	6
About CRM.....	7
Performance Overview.....	8
KPI Scorecard.....	8
CRM's Financial Performance.....	9
Recruitment & Study Coordinator Performance.....	10
Sponsored Research in Malaysia.....	11
Classification of Clinical Trials.....	12
Top Sites According to Therapeutic Areas in 2019.....	14
Site Recruitment Achievement in 2019.....	15
CRM Sponsored Research Awards.....	16
Feasibility Study Report.....	17
Growth of Sponsors & CROs.....	19
Placement & Growth of Study Coordinators.....	20
CRM News Coverage.....	21
Highlights of 2019.....	22
Audit Activities.....	24
Trainings & Workshops.....	25
Global Partnerships.....	26
Publications.....	27
CRM in Photos.....	28
What's Next in 2020.....	30



# FOREWORD

Ladies & Gentlemen, I'm proud to present you CRM's 2019 Annual Report.

In 2015, Clinical Research Malaysia had initiated 5 key strategies to build the foundation in making Malaysia the preferred destination for sponsored research. We have since then remained steadfast in carrying out these key strategies in ensuring the deliverance of clinical research to the expectations of our stakeholders. As we approach the end of the year, 2019 has been the perfect embodiment of our efforts to reach that vision.

With 2019 marking the beginning of CRM to be a self-sufficient company, much of the key decisions made has been to ensure a sustainable growth of the company as well as the clinical research industry. CRM's socio-economic contribution to the country in terms of growing clinical research has been further enriched with the partnerships and collaborations it has formed over the years with international organisations such as Hematogenix, FIND and Singapore's National University Health Systems. Furthermore, having been certified with ISO 9001:2015, CRM is also tasked in retaining this certification and in ensuring the Quality Management System is tickled down to our very grassroots in operations.

With all this in place, it comes with no surprise that we have performed well during the audit by the National Audit Department which recognized CRM as being an efficient company in the management of clinical research. Clinical research was delivered with speed, reliability and quality. Apart from the ISO accreditation, we have also successfully gained trust among our stakeholders; 84% of good and above rating for our Study Coordinators, 83% recruitment rate and improved study start-up time by 50% from over 300 days to 150 days.

All of these would not be possible without the excellent work by our Principal Investigators (PI), Study Coordinators (SCs) and Clinical Research Centers (CRC). Some of these sites and study teams have even received international accolades from the study sponsors and this are a testament to how far the clinical research landscape in Malaysia have grown and developed. One of such examples is the oncology team from Hospital Kuala Lumpur which were recently recognized as global first recruiters in a sponsored trial involving at least 10 nations for patients with advanced or metastatic breast cancer study. It was a great wrap to the year as we lay witness to the accreditation of CRC Sarawak General Hospital under the Phase 1 Accreditation Program, a tremendous leap in First-in-Human research in Malaysia and in CRM's Phase I Realisation Project.

Thank you to all who have worked with us in steering the clinical research industry forward in Malaysia. Moving forward, as we proactively seek continuous improvement in our day-to-day processes, CRM also hopes to explore opportunities and innovations to improve our services to our stakeholders. These are especially important for CRM to continually enhance our performance as we strive to focus on operational excellence moving forward in 2020.



**Dr. Akhmal Yusof**  
CEO, Clinical Research Malaysia

## BOARD OF DIRECTORS

CRM's Board of Directors comprised of prominent individuals who are representatives from the Ministry of Health, university hospitals and the pharmaceutical industry.



Chairman

**YB Datuk Seri Dr. Dzulkefly Ahmad**

Minister of Health, Malaysia

*(Term: 21 May 2018 - 24 February 2020)*



**Y. Bhg. Dato' Seri Dr. Chen Chaw Min**

Secretary General, Ministry of Health, Malaysia



**Y. Bhg. Datuk Dr. Noor Hisham Abdullah**

Director General of Health, Malaysia



**Y. Bhg. Dato' Dr. Goh Pik Pin**

Director, National Clinical Research Centre, Malaysia



**Y. Bhg. Datuk Dr. Shahnaz Murad**

Former Deputy Director General of Health (Research & Technical Support)



**Prof. Dr. Abdul Rashid Abdul Rahman**

Medical Director and Senior Consultant Physician, An Nur Specialist Hospital



**Mr. Ewe Kheng Huat**


Executive Director of the Pharmaceutical Association of Malaysia



**Prof. Datuk Dr. A. Rahman A. Jamal**

Pro Vice Chancellor, Universiti Kebangsaan Malaysia (UKM)

# ORGANIZATION CHART




CRM Team | National Conference 2020



# ABOUT CRM

## Our Vision and Mission



## Our Core Values



## CRM's Core Services





# PERFORMANCE OVERVIEW

## KPI Scorecard



Figure 1: KPI Scorecard from 2012 - 2019

CRM's conception goals were to create 1000 new skilled jobs, conduct 1000 sponsored research and produce GNI of RM 578 million by 2020. The data collected in 2019 shows CRM being very close to achieving all targets set, with two having been achieved since 2017 (Figure 1). CRM is confident in achieving the GNI target by end of 2020, with another RM52 million in CTA values to capture (Figure 2).



Figure 2: Cumulative GNI from Sponsored Research until 2019



## CRM's Financial Performance

Since early 2019, CRM has taken additional measures towards self-sustenance of the company and this has been evident with CRM's 2019 financial performance (Figure 3), bridging the gap of income and expenses down to 20% (Figure 4). One of the major income earners in CRM are from the CRM management and study coordinator fees. In ensuring a smoother yet transparent transaction of these payments, the Finance team has introduced the payment tracker that facilitate study team as well as sponsor/ CRO with timely reimbursements.




Figure 3: Clinical Research Malaysia Finance Performance in 2019




Figure 4: CRM's self-sustainability performance from 2015-2019 (Income / Expenses)

CRM's has also capitalised in its website and social media reach with more than 66% increase in the number of visits and impressions in 2019 compared to 2018 (Figure 5). This shows the growing traction CRM posts have been gaining from its local and global audience alike.




Figure 5: CRM website/ social media visits & impressions from 2016 - 2019

## Recruitment & Study Coordinator Performance

In CRM's Clinical Operations team, the concept of speed, quality and reliability are factored in the performance of CRM's study coordinators. Feedbacks from stakeholders are tabulated as a measurement on the overall accomplishment of study coordinators. Study recruitment is also frequently monitored, and challenges faced are explored together with discussion between study team and sponsor. All these have led to positive data in terms of recruitment achievement and study coordinators performance in 2019 (Figure 6).




Figure 6: Clinical Operations Performance in 2019

\* Average percentage of recruitment achieved between 2018-2019 in studies involving CRM study coordinators

\*\* Data from CRM Customer Satisfaction Survey in June 2019

## Sponsored Research in Malaysia

In 2019, a total of 162 sponsored research was approved by Medical Research and Ethics Committee (MREC) and Institutional Review Boards/Independent Ethics Committees (IRB/IECs) (Figure 7). The numbers of sponsored research showed steady trend over the past few years and this translates to how Malaysia is viewed as a reliable site for clinical research.




Figure 7: Number of Sponsored Research from 2012 – 2019



Figure 8: Number of Sponsored Research in MOH sites from 2012 - 2019

Data sourced from MREC shows the trend has also been constant in Ministry of Health (MOH) facilities (Figure 8). More importantly, when both data are observed together, it is noted that over 70% of sponsored research conducted are also conducted in MOH facilities, showing the recognition these sites have gained owing to its performance in terms of quality and recruitment. In addition, majority of patients who seek treatment in public hospitals could access to new innovative drugs through clinical research.

## Classification of Clinical Trials

Interventional trials accounted for the largest proportion of trials in Malaysia in 2019, with 66 trials (66%) involving new investigational products, 26 (26%) bioequivalence studies and 7 (7%) medical device trials (Figure 9). New investigational products comprise of drugs, biologics, biosimilars or supplements. Out of all interventional trials, Phase III trials records the highest number of trials followed by, bioavailability/bioequivalence (BA/BE) studies, Phase II, Phase IV and Phase I (Figure 10).




Figure 9: Breakdown of studies according to intervention, 2019




Figure 10: Classification of interventional studies in Malaysia, 2019



Disease patterns in Malaysia are almost like those in developed countries. Malaysian patients have similar unmet medical needs that these countries have. Cancer and cardiovascular disease are the major cause of mortality and morbidity in Malaysia. The high incidence of these noncommunicable diseases provides a large patient pool for clinical trials in these therapeutic areas. In 2019, oncology trials accounted for the highest number of trials followed by haematology and cardiology trials (Figure 11). Meanwhile, University Malaya Medical Centre was recorded to have the highest number of trials in Malaysia for 2019 followed by Hospital Pulau Pinang, Hospital Ampang and Sarawak General Hospital (Figure 12).





Figure 11: Number of Sponsored Research conducted according to therapeutic area in Malaysia, 2019



Figure 12: Top sites awarded with sponsored research in Malaysia, 2019

## Top Sites According to Therapeutic Areas in 2019

Below are the top clinical trial sites in 2019 for the field of Oncology, Haematology/ Hemato-Oncology, Cardiology/Vascular Disease, Paediatrics/Neonatology and Infections & Infectious Diseases. CRM has been involved in the trials at most of the Ministry of Health sites, whereby it has assisted investigators in the review of the study budget and clinical trial agreement, as well as in providing study coordinators.



## Site Recruitment Achievement in 2019

In Malaysia, to date, there have been 160 study sites that have participated in sponsored research of which almost 67% are public hospitals and government clinics within the Ministry of Health. Many of these sites have performed and delivered the research to the quality and standards as per the Good Clinical Practice (GCP). Reliability is also an important factor in these site performances as achievement of recruitment as per the target and time set creates a more positive statement on Malaysia performance. In 2019, some of these sites/ investigators have earned special recognition from sponsors for their recruitment achievement in global sponsored trials (Figure 13).




Figure 13: Site recruitment achievement in global trials, 2019

## CRM Sponsored Research Awards

The CRM Sponsored Research Award is given out each year to outstanding Principal Investigators, clinical trials sites and the industry for their contribution in sponsored research to the nation. Below are the recipients of the CRM Sponsored Research Awards 2019.

### INVESTIGATOR & TOP RECRUITER OF THE YEAR - DR. VOON PEI JYE



Dr Voon Pei Jye received the Investigator of the Year & Top Recruiter of the Year Award. For Investigator of the Year Award, he conducted the most studies that were initiated in 2018 and has the highest number of oncology trials in that year. He was also PI for 7 studies that was approved in 2018, one of which is a Phase 1, dose escalation study. He also co-authored in 3 publications in 2018 and 8 of his research findings were presented in ESMO Munich, ESMO Asia, World Conference on Lung Cancer, EndoBarcelona and Malaysia-Singapore Congress of Medicine.

For the Recruiter of the Year Award, Dr Voon has achieved first-patient-in within 100 days from site activation in 5 of his studies initiated in 2018. Four out of these 5 studies to date, have successfully reached its recruitment target.



### SPONSOR OF THE YEAR



Merck Sharp & Dohme (Malaysia) received the Sponsor of the Year Award for bringing in the highest number of studies that got initiated in 2018 and contributing to the highest value of sponsored research brought to the country.

## CLINICAL TRIAL SITE OF THE YEAR

### HOSPITAL PULAU PINANG

Hospital Pulau Pinang received the Clinical Trial Site of the Year Award for having conducted the highest number of sponsored research among all MOH sites. 27 sponsored research were conducted at this site in 2018, spanning 13 different therapeutic areas including areas of hematology, infectious disease, nephrology, gastroenterology, oncology and bioequivalence studies.



### CRO OF THE YEAR



IQVIA received the CRO of the Year Award with the highest number of studies and sites initiated in 2018 (9 studies and 22 sites), and having achieved over 71% of the total recruitment from the 22 sites activated.



## Feasibility Study Report

Feasibility studies are the gateway to bringing in more clinical trials to Malaysia. It is not only a tool to assess whether a trial is possible to be conducted in Malaysia, but also a method to promote that possibility to sponsors and CROs who may not be familiar with Malaysia's demographics, disease pattern and research sites.

CRM's feasibility service is provided complimentary to sponsors and CROs who may be interested in conducting clinical trials in Malaysia. Parallel with the growth of sponsors and CROs who have utilized CRM's services, the number of full feasibilities received from 2016 to 2019 recorded a steady growth from 98 in 2016 to 137 in 2019. CRM also assisted with pre-feasibility enquiries which are also known as country level feasibility (Figure 14). Most feasibility studies received in 2019 were studies in oncology followed by gastroenterology, haematology and paediatrics (Figure 15).




Figure 14: Pre-Feasibility & Full Feasibility from 2016 -2019




Figure 15: Full Feasibilities received in 2019 by therapeutic area

Table 1 shows the top five indications of the five highest therapeutic areas of feasibility received from 2015 to 2019.

Table 1: Top indications from the five highest feasibilities by therapeutic area received from 2015 to 2019

Top 5 Full Feasibilities Received from 2015–2019 by Therapeutic Area	Top 5 Indications
<b>Oncology</b>	<ul style="list-style-type: none"> <li>• Non-Small Cell Lung Cancer (NSCLC)</li> <li>• Breast Cancer</li> <li>• Gastric/Gastroesophageal Junction Cancer</li> <li>• Colorectal Cancer</li> <li>• Head and Neck Cancer</li> </ul>
<b>Gastroenterology</b>	<ul style="list-style-type: none"> <li>• Ulcerative Colitis</li> <li>• Hepatitis B</li> <li>• Crohn's Disease</li> <li>• Non-alcoholic steatohepatitis (NASH)</li> <li>• Diabetic Gastroparesis</li> </ul>
<b>Haematology</b>	<ul style="list-style-type: none"> <li>• Lymphoma</li> <li>• Hemophilia</li> <li>• Leukemia</li> <li>• Thalassemia</li> <li>• Paroxysmal Nocturnal Hemoglobinuria</li> </ul>
<b>Paediatrics/Neonatology</b>	<ul style="list-style-type: none"> <li>• Pediatric Respiratory Syncytial Virus</li> <li>• Pediatric Diabetes</li> <li>• Pediatric partial-onset seizures</li> <li>• Pneumococcal Vaccine</li> <li>• Pediatric Lymphoma</li> </ul>
<b>Infections and Infectious Diseases</b>	<ul style="list-style-type: none"> <li>• Ventilator acquired pneumonia</li> <li>• Influenza A</li> <li>• HIV</li> <li>• Hospital Acquired Pneumonia</li> <li>• Antimicrobial Resistance</li> </ul>

## Growth of Sponsors & CROs

It is also important that Malaysia is viewed as a preferred destination in clinical research and since its establishment in June 2012, CRM has been promoting Malaysia's capabilities and capacities in clinical research. The growth of sponsors and CROs that have engaged with CRM has been evident in showing the growing effect Malaysia has in the global clinical trial landscape (Figure 16). Many of these global Sponsors & CROs also contribute to the number of sponsored research awarded (Figure 17).



Figure 16: Sponsors & CROs that have engaged with CRM




Figure 17: Top 11 contributors in number of sponsored research by Sponsors & CROs for 2019

## Placement & Growth of Study Coordinators

In its infancy in 2012, CRM had 22 study coordinators that were placed throughout Malaysia at various sites conducting sponsored research and this number have grown to 130 in 2019 (Figure 18). CRM has expanded its operations beyond the realm of Ministry of Health sites, to include university hospitals & private hospitals




Figure 18: Growth of number of CRM Study Coordinators from 2016-2019



## CRM NEWS COVERAGE

### Malaysia Collaborates with Two Prominent Singapore Organizations to Advance Clinical Research



KUALA LUMPUR, 26 February 2019 - Clinical Research Malaysia (CRM) inked two Memorandum of Understanding (MoU) with Cytomed Therapeutics (a spinoff company from Singapore's A\*Star) and National University Health System (NUHS), Singapore. This MoU will further pave the way for better Malaysia-Singapore collaborations in advancing drug development and research capabilities between both countries.

### Creating an Impactful Clinical Trials Day at Tunku Azizah Women and Children Hospital, KL



KUALA LUMPUR, 29 August 2019 - Clinical Trials Day 2019 was celebrated for its third consecutive year at the newly opened Tunku Azizah Women and Children Hospital, Kuala Lumpur. Held in collaboration with Clinical Research Centre of Kuala Lumpur Hospital, this program aims to elevate the awareness level of clinical trials in the country as well as to encourage participations of medical professionals in clinical research. During this one-day event, Sponsored Research Awards were presented to individuals and organizations that have immensely contributed to clinical research in Malaysia.

### Sarawak GH is Ready for First-in-Human Studies



KUCHING, 10 December 2019 – CRC Sarawak General Hospital received the provisional certificate from the National Pharmaceutical Regulatory Authority (NPRA) and is now listed under NPRA's Phase I Unit Accreditation Programme. CRC Sarawak General Hospital is the first site in Malaysia to be listed in this program.

### Ministry of Health Supports Clinical Research for More Innovative Treatment Options for Malaysians



PUTRAJAYA, 19 December 2019- The Secretary General of the Ministry of Health, Dato' Seri Dr Chen Chaw Min launched CRM's I AM AWARE Photography Series at the Health Ministry complex, Putrajaya. The series feature a photo collection of real-life patients that have participated in a clinical trial, portraying their experiences at different stages of a clinical trial patient's life. This will be incorporated in the I Am AWARE programme which aims to elevate the awareness level of clinical trials among patients and the general public.

## HIGHLIGHTS OF 2019



### **DIA Singapore Annual Meeting 2019**

March 5-6

CRM was part of the Program Committee for the DIA-CoRE Singapore Annual Meeting 2019 which was jointly organised by the Drug Information Association and Centre of Regulatory Excellence – Duke-NUS Medical School.



### **4th National Hepatitis Conference, Kuala Lumpur**

March 7-9

CRM was present as an exhibitor during the 4th National Hepatitis Conference, organised the Gastroenterology & Hepatology Unit, Ampang Hospital. We also participated as a panellist, discussing on a collaborative R&D model in hepatitis, which remains a public health concern in Malaysia.



### **Global Clinical Platform (GCP) Symposium, Tokyo, Japan**

March 12

CRM was invited as a panellist in the GCP symposium to showcase Malaysia's value proposition to Japanese Bio-tech companies. Organised by Intellim Japan, this program was attended by key opinion leaders, regulators as well as healthcare professionals from Japan and abroad.



### **DIA Asia 2019 International Conference, Tokyo, Japan**

April 18-19

CRM was invited to talk on 'Enhancing the Environment for Sponsored Research in Malaysia' during the DIA Asia 2019, a forum in Asia for drug development in the new era.



### **DIA 2019 Global Annual Meeting, San Diego, USA**

June 24-26

The Drugs Information Association (DIA) meeting is where more than 5000 professionals in the pharmaceutical, biotechnology and medical device communities from 55 countries around the globe are present. CRM participated through booth exhibition to promote Malaysia's strong clinical research environment to the global audience.





### **Phase I Conference, Manchester, UK July 14 -16**

CRM were delegates to the inaugural conference organised by Manchester Cancer Research Centre together with the Experimental Cancer Medicine Centres. We also had the opportunity to schedule a visit The Christie at Manchester, a site where more than 300 early phase oncology trials are carried out yearly.



### **ESMO Congress, Madrid, Spain September 27- October 1**

CRM participated as a booth exhibitor in the European Society of Medical Oncology (ESMO) Congress, which is home to all oncology stakeholders, comprising of 18,000 oncology professionals from over 150 countries.



### **REACTA Annual Forum 2019, Chiba, Japan November 15**

As a founding member of the REACTA (Regional Asian Clinical Trial), CRM was at the REACTA Annual Forum at Chiba University to speak on the collaboration between academia, the industry and government in catalysing clinical research in Malaysia.

#### **Other local events CRM was involved in include:**

- NHAM-CRM Research Track
- ASCOMOS-CRM Research Track
- 13th MOH-AMM Scientific Meeting
- National Cancer Survivors Day by NCSM
- Malaysian Association for Cancer Research Scientific Conference

# AUDIT ACTIVITIES

## Ensuring Best Practise in Corporate Governance - An Audit by National Audit Department



In 2019, Clinical Research Malaysia was audited by the National Audit Department and was the sole agency within the Ministry of Health that was chosen for this purpose. The objectives of the audit were to evaluate the administration and management of the company, to review CRM's financial standings and to evaluate the management of its activities.

The audit activity spanned for 5 months and included site audits at Hospital Pulau Pinang, Hospital Kuala Lumpur and Sarawak General Hospital. The findings were presented to the Parliament Public Accounts Committee (PAC) in December 2019.

The overall report indicates that CRM has achieved its establishment objective, met satisfactory corporate governance and has stable financial position. Commendations were made on CRM's marketing activities which showed efficient social media approach and branding with minimal expenditure. Key recommendations were also made in the report to further ensure the sustainability of the company. A copy of the report is made available online at the National Audit Department website.

## Continuous Improvement in Maintaining ISO 9001:2015 Quality Management System

Clinical Research Malaysia was certified with the Quality Management System (QMS) ISO 9001:2015 by SIRIM QAS in January 2019. In ensuring compliance to the QMS in place, surveillance audit by SIRIM is conducted annually until re-certification, hence in December 2019, CRM underwent and passed its 1st surveillance audit.

CRM also takes a proactive approach in ensuring practices are reviewed through continuous improvement exercises within the organisation to ensure quality of the processes performed are delivered.





# TRAININGS & WORKSHOPS



## Developing Study Coordinators

CRM has continued to provide relevant trainings to its study coordinators to uphold the quality of each trial. Following this, CRM has successfully organised six TIPS Training (Training to Improve Performance of Study Coordinators) which included Good Documentation Practices, study file management, protocol deviation reporting as well as updates to the ICH GCP E6 R2. In addition, all study coordinators underwent intensive 2-day training during the yearly National Conference held in January 2019 where workshops and oncology specific training by Bayer, George Clinical and Covance were conducted.

## GCP Refresher/ Protocol Compliance Workshops

CRM has also made knowledge training for investigators in Malaysia a priority especially as per the Good Clinical Practice (GCP). Following this, CRM has conducted nine GCP Refresher courses as well as two Protocol Compliance workshops for investigators throughout Malaysia.



## Nurturing New Talents in Sponsored Research

In the year 2019, CRM has successfully conducted a total of six workshops at various regions in Malaysia. These platforms provide local investigators insights on how to conduct clinical trials at depth and allow them to gain a better outlook on how a clinical trial journey looks like especially with CRM's role and support in Malaysia's landscape.

## Grant/ Protocol Writing Workshops

CRM has conducted two workshops on protocol and grant writing in 2019, which saw the participation of close to 80 university researchers as well as medical professionals. Facilitators Dr Albiruni Razak (University of Toronto, Canada) and Dr Masliza Mahmood (University of Oxford, UK) shared their experience and thoughts in producing high quality research applications that are to the standards of the international scientific community.



# GLOBAL PARTNERSHIPS

CRM has partnered with several global organisations over the years in advancing clinical research in Malaysia through collaborations in global studies, strategic business expansion and development of human capital.



## Australia

- Novotech

## Canada

- Prince Margaret Hospital

## China

- First Affiliated Hospital of Zhejiang University

## Japan

- Intellim Corporation

## Singapore

- Cytomed Therapeutics
- National University Health Systems

## South Korea

- C&R

## Switzerland

- Foundation for Innovative New Diagnostics

## Taiwan

- Taipei Medical University

## United Kingdom

- The Christie Manchester

## USA

- Hematogenix



# PUBLICATIONS

CRM has published 7 articles in peer-reviewed journals, sharing on the clinical research landscape of Malaysia as well as on its accomplishment in speed and quality through CRM's services and activities.





# CRM IN PHOTOS



ISO 9001: 2015 Certification by SIRIM QAS International, 19 January



Phase 1 Scientific Review Panel (SRP) Meeting, 14 February



CRM's Office Launch by the Minister of Health, Malaysia, 26 February



CRM 1st Board of Directors Meeting 2019, 26 February



MoU between CRM & NUH (Singapore), 26 February



MoU between CRM & CytoMed, 26 February



1st GCP Symposium Progress in Asian Clinical Trials, 12 March



NHAM-CRM Research Track 2019, 13 April



NERCIM, 17 April



CRM Investigator Dialogue 2019/1, 25 April



CRM Industry Dialogue 2019/1, 24 April



Meeting with Pharmaniaga Berhad, 8 April



Meeting with Merck Sharp & Dohme (MSD), 15 May



# CRM IN PHOTOS



Parexel Quarterly Alliance Site Update, 16 May



Visit to Health Sciences Authority (HSA)  
Singapore, 17 May



Meeting with Sunway Medical Centre,  
19 June



Meeting with My Dental International  
Clinics Sdn Bhd, 26 June



Meeting with Bayer, 25 July



Visit by Prof James from  
the University of Southampton, 25 July



Talk by Dr Albiruni Razak at the National  
Health Institute, 12 August



Meeting with Novo Nordisk, 16 August



Visit by Hematogenix, 11 September



Meeting with Parexel, 20 September



Meeting with Prof Yuji Kumagai (Kitasato University)  
& Mr Koichi Hagita (TryAngle), 20 September



ESMO Congress 2019,  
27 September - 1 October



Meeting with Fresenius Medical Care, 17 October



Meeting with Legal Advisor & Secretary Division  
of Policy and International Relations of MOH, 23 October



Meeting with Henlius Biotech Inc.,  
25 October



REACTA Annual Forum 2019, 18 November



Meeting with Intervenn Biosciences, 27 November



Meeting with Syneos Health, 4 December



## WHAT'S NEXT IN 2020

Moving forward in 2020, CRM will be conceptualising **operational excellence** in all its departments which embraces principle and tools necessary to create sustainable growth. Much of this will be on building and strengthening its efforts on the current key strategies that will be focused on growing PI & ISR, collaborating with stakeholders, creating awareness of clinical research and developing human capital. Value and delivery of CRM services to stakeholders will be improved through quality, engagement and innovation which would ensure continuous improvement in speed and reliability. CRM shall also remain steadfast on the Phase I Realization Project (PIRP) where stronger efforts will be driven to bring in more Phase I clinical trials to Malaysia.




*CRM Annual Report 2019 was prepared by the Business Development Department of Clinical Research Malaysia*

# Do you or someone you know have *medical conditions?*

*such as cancer, diabetes, heart disease and others*

Visit the link below to find a clinical trial near you  
**[www.clinicalresearch.my/fact](http://www.clinicalresearch.my/fact)**

## REGISTER FOR CLINICAL TRIAL VIA FACT WEBSITE



## PARTICIPATING IN A CLINICAL TRIAL - What you need to know



For more information, please send us a message via **Whatsapp** at **016-320 0376** or email to **[contact@clinicalresearch.my](mailto:contact@clinicalresearch.my)**



[www.clinicalresearch.my](http://www.clinicalresearch.my)



CERTIFIED TO ISO 9001 : 2015  
CERT. NO. : QMS 03360



CERTIFIED TO ISO 9001 : 2015  
CERT. NO. : QMS 03360